Deutsche Bank analyst James Shin lowered the firm’s price target on Eli Lilly (LLY) to $1,015 from $1,025 and keeps a Buy rating on the shares. Following the Q3 earnings report, it wouldn’t be surprising if the Street checks Zepbound scripts and inventory “a bit more closely,” the analyst tells investors in a research note. That said, the firm believes GLP1 demand is still healthy. Lilly remains the best growth story among U.S. large-cap biopharma, contends Deutsche Bank.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Eli Lilly earnings selloff brings buying opportunity, says JPMorgan
- Eli Lilly price target lowered to $1,100 from $1,150 at BofA
- Eli Lilly price target lowered to $975 from $1,025 at Barclays
- Eli Lilly’s Robust Q3 2024 Revenue Growth Driven by New Products
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
